Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by ORIC Pharmaceuticals

< Previous 1 2 Next >
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.